Introduction {#s0005}
============

Rhabdoid glioblastoma (R-GBM) is a very rare disease with few cases reported [@bb0005; @bb0010; @bb0015; @bb0020; @bb0025; @bb0030; @bb0035; @bb0040]. R-GBM is characterized by tumor cells that resemble rhabdomyoblasts [@bb0010], which robustly express vimentin, epithelial membrane antigen (EMA), and SMARCB1 (INI-1), but only faintly express glial fibrillary acidic protein (GFAP) [@bb0025; @bb0035; @bb0045; @bb0050]. Clinically, R-GBMs can occur at any age but most commonly occur in teenagers younger than 20 years old [@bb0005; @bb0010; @bb0025].

Chromosome 22, which is frequently lost in atypical teratoid rhabdoid tumors (ATRT), is often deleted in these tumors [@bb0015; @bb0040], although this finding is inconsistent [@bb0005]. In one case, copy number gains were noted for chromosomes 3, 7, 9, 12, 17q, and 21q [@bb0005] in R-GBM. Also, in a case series, copy number gain or amplification of *EGFR* on chromosome 7 was noted [@bb0045]. Regarding genetic changes prevalent in brain tumors, *CDKN2A* hemizygous deletion was reported in one case [@bb0010]. Otherwise, *BRAF* mutations were absent in two cases that were examined [@bb0055], and *SMARCB1* (INI-1) [@bb0060; @bb0065], which is important in ATRT, was not mutated in R-GBM [@bb0010].

Presently, R-GBM is not recognized as a distinct disease entity by the World Health Organization [@bb0070] classification system because accumulated information on this rare variety is still rudimentary. To our knowledge, no study has evaluated the genome-wide profile of this disease except for one case that was evaluated using array comparative genomic hybridization (CGH) [@bb0005]. To determine whether R-GBM should be recognized as a disease that is distinct from conventional glioblastoma (GBM) or other tumors with similar characteristics such as ATRT, comprehensive genomic data will be fundamental for diagnostic, prognostic, and therapeutic decisions.

A 20-year-old female presented with a rim-enhanced tumor that was pathologically proven to be an R-GBM. She underwent two extensive surgeries and concurrent chemoradiotherapy combined with oral temozolomide treatment. She was free of disease for 25 months after the treatment. Using next generation sequencing techniques, we studied this tumor to obtain novel insight into identifying distinctive genetic changes in an R-GBM compared to conventional GBM as well as normal brain tissue. We performed whole exome sequencing (WES), whole transcriptome sequencing (WTS), single nucleotide polymorphism (SNP) array, and array-CGH. The aims of this study were to investigate the genomic profile of R-GBM and to explore whether R-GBM had a distinct genomic signature that could be used as a therapeutic target.

Materials and Methods {#s0010}
=====================

Study Patient {#s0025}
-------------

A 20-year-old female patient was seen in an outpatient clinic at Seoul National University Hospital because of headache, nausea, and vomiting in April 2011. Brain magnetic resonance imaging showed a 5-cm sized, well-enhanced mass in the right temporal lobe. The mass also showed diffusion restriction with increased perfusion at the peripheral enhanced portion. She underwent a craniotomy for tumor removal in May 2011. The molecular genetic characteristics of the surgical specimen were evaluated as follows. Immunohistochemical staining revealed focal expression of GFAP and strong expression of EMA and INI-1 ([Figure 1](#f0005){ref-type="fig"}). Fluorescence *in situ* hybridization (FISH) showed no *EGFR* amplification and no deletion of chromosomes 1p, 9p21, or 19q. In addition, methylation-specific PCR showed hypermethylation of the *MGMT* promoter, and the MIB-1 labeling index was measured as 36.5% with an Aperio Spectrum plus image analyzer. The study patient received adjuvant concurrent chemoradiotherapy with oral temozolomide treatment after the surgery. However, the tumor recurred on the ipsilateral side of the frontal lobe, and she underwent a second operation to remove the recurrent tumor. The final pathology confirmed that, as with the initial mass, the recurrent tumor was an R-GBM. The recurrent tumor had a MIB-1 labeling index of 37.5%. She has been free from disease for 25 months as of December 2013. The study protocol was reviewed and approved by the institutional review board of the Seoul National University Hospital, and informed consent was obtained from the study patient. The recommendations of the Declaration of Helsinki for biomedical research involving human subjects were followed.

DNA and RNA Preparation {#s0030}
-----------------------

Fresh frozen tumor tissue and 5 ml peripheral blood were obtained at the time of the first surgery. The DNeasy® Blood & Tissue Kit (Qiagen, Hilden, Germany) was used to extract genomic DNA and tumor DNA, according to the manufacturer's recommendations. Extracted DNA was quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). RNA was extracted from the tumor tissue using TRIzol (Invitrogen, Grand Island, NY) and eluted in RNAse-free water. RNA quantity and quality were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA).

Whole Exome Sequencing {#s0035}
----------------------

We used the Agilent SureSelect50-Mb ExomeCapture Kit for exon target enrichment (Agilent Technologies Inc.). Sequencing was performed using the Illumina HiSeq2000 (Illumina Inc., San Diego, CA) with 100-bp paired-end reads. Using UCSC hg19 as a reference genome, mapping and pairing were performed with the Burrows-Wheeler Aligner (BWA) algorithm [@bb0075]. Local realignment was performed using Genome Analysis ToolKit (GATK) [@bb0080], and duplication removal was conducted using Picard.

Somatic calling of somatic single nucleotide variants (SNVs) and indels is described in Supplement 1. Using SnpEff [@bb0085], we selected variations that were non-synonymous and rare in the general population (defined as \< 1% in the 1000 genome project (<http://www.1000genomes.org/>)). For copy number alteration (CNA) analysis of WES data, we used the Copy Number Analysis for Targeted Resequencing (CONTRA) tool [@bb0090] and summarized the exon-level log2 fold changes of read depth between the normal and tumor samples into gene-level log2 fold changes. Loss of heterozygosity (LOH: heterozygous in normal tissue but homozygous in the tumor) analysis also was performed using WES. We used variant allele fraction values of normal and tumor samples to determine the LOH region.

Whole Transcriptome Sequencing {#s0040}
------------------------------

The 200- to 500-bp double-stranded cDNA fragments were purified by agarose gel electrophoresis and amplified using PCR to produce the library. Raw sequencing reads were produced by Illumina HiSeq 2000 with 100-bp paired-end reads. After removing noisy raw reads, which contained the adaptor sequence and more than 10% unknown bases or low quality bases, the remaining reads were aligned with the human reference genome (UCSC hg19). To find fusion transcripts, we utilized three types of fusion discovery software: deFuse [@bb0095], BreakFusion [@bb0100], and ChimeraScan [@bb0105]. UniGene clusters were downloaded from the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/) to assist in locating potential gene fusions. To quantify the gene expression level, the number of reads that mapped to the exons of each RefSeq gene was calculated, and the corresponding reads per kilobase per million reads (RPKM) [@bb0110] value was derived. Possible functional fusions were annotated using Oncofuse [@bb0115] and went through further analysis.

SNP Array {#s0045}
---------

We applied a genome-wide SNP array (Illumina HumanOmni5-Quad BeadChip, Illumina) using the genomic DNA sample. With B allele frequency data from GenomeStudio (Illumina) analysis results for SNP array data, we used the paired parent-specific circular binary segmentation method for LOH and CNA analysis.

Array Comparative Genomic Hybridization and Identification of CNAs {#s0050}
------------------------------------------------------------------

We used the Agilent aCGH G3 Human 1×1M array with tumor and matched normal genomic DNA samples. Raw data were acquired and normalized using the locally weighted scatterplot smoothing (LOWESS) algorithm using Feature Extraction software ver10.7 (Agilent software). The significance test for each CNV region used the Z-statistic calculated by DNA Analytics ver4.0.81 (Agilent software), which sets the window size to 1M and Z-score threshold to 4.0.

Use of the Public Database as a Reference {#s0055}
-----------------------------------------

We used gene expression data estimated from WTS to select possible functional genetic changes in our study. Because R-GBM is a rare disease and obtaining control samples is not easy, we used a public database as a reference. First, we compared the RPKM value of specific genetic changes found in our analysis with normal brain expression values. Then, we compared the RPKM value of specific genetic changes found in our analysis with GBM data to determine whether R-GBM is simply a subtype of GBM. For the normal brain data, we used the normalized expression dataset from BrainSpan (<http://www.brainspan.org/>). For the GBM data, we used datasets from TCGA (<https://tcga-data.nci.nih.gov>) and cBioPortal for Cancer Genomics (<http://www.cbioportal.org>).

Results {#s0015}
=======

Tumor Purity, Alignment, and Coverage Statistics {#s0060}
------------------------------------------------

The purity of the tumor samples was estimated using SNP array data with the Allele-specific copy number analysis of tumors (ASCAT) algorithm [@bb0120]. The proportion and the ploidy of tumor cells in the sample were about 89% and 2.17, respectively (Online Resource Section 1: Supplementary Figure 1). In WES, the total numbers of uniquely mapped reads were 181,350,341 and 186,695,100 for normal and tumor samples, respectively. These data yielded mean target coverages of 210 and 197 for the samples, respectively (Online Resource Section 2: Supplementary Table 1).

Somatic SNVs and Small Indels Found With WES {#s0065}
--------------------------------------------

We found 46,468 (45,045 in dbSNP138) and 46,191 (44,748 in dbSNP138) SNVs from the paired normal DNA and tumor DNA, respectively. A total of 45,542 (44,264 in dbSNP138) SNVs were commonly observed in both samples. We identified 3753 (3362 in dbSNP137) and 3678 (3314) small indels from the paired normal and tumor DNA, respectively. A total of 3594 (3273 in dbSNP138) small indels were common in both samples (Online Resource Section 3 and 4: Supplementary Figures 2--4). The somatic calling method is described in the Supplement Text (Online Resource Section 4). As a result, 38 somatically mutated SNVs and one small indel were detected with WES. Twenty-three non-synonymous SNVs ([Table 1](#t0005){ref-type="table"}) were found, 13 of which were also found with WTS.

Loss of Function SNVs and Analysis of Small Indels (Online Resource Section 5) {#s0070}
------------------------------------------------------------------------------

The candidates for loss of function were selected from the nonsense, splice junction, and frameshift variants (Supplementary Table 3 of Online Resource Section 5).

Whole Chromosome Copy Gains and Losses {#s0075}
--------------------------------------

Gains were identified in chromosomes 3, 7, and 9 from the SNP array and WES data ([Figure 2](#f0010){ref-type="fig"}). Interestingly, chromosome 9 showed a homozygous deletion of the 9p21 locus that contains the tumor suppressor genes *CDKN2A* and *CDKN2B* ([Figure 2](#f0010){ref-type="fig"}*B*).

CNA Analysis Using WES and Array-CGH {#s0080}
------------------------------------

CNA data were generated from array-CGH and WES. First, CNAs were analyzed with array-CGH with probe-based CNA and interval-based CNA. The probe-based method revealed that more than 80,000 CNA regions were present in tumor tissue compared to paired normal tissue. The interval-based method revealed 370 tumor-specific CNA regions. WES analysis identified 323 regions with CNAs, which included 11 genes that are well-known tumor suppressors and oncogenes [@bb0125; @bb0130]: *VHL*, *CTNNB1*, *PIK3CA*, *EGFR*, *CDK6*, *MET*, *EZH2*, *MLL3*, *CDKN2A*, *CDKN2B*, and *NOTCH1* ([Table 2](#t0010){ref-type="table"}). In addition, WES, SNP array, and array-CGH analyses showed that *CDKN2A/2B* were homozygously deleted. Copy number gain was observed for *CTNNB1*, *CDK6*, *VHL*, *MLL3*, *EZH2*, *PIK3CA*, *EGFR*, *NOTCH1*, and *MET* with WES and SNP array analyses.

Fusions Found With WTS {#s0085}
----------------------

A total of 376 fusions were observed with WTS with deFuse [@bb0095], BreakFusion [@bb0100], and ChimeraScan [@bb0105]. Interchromosomal fusions and intrachromosomal fusions \> 50 kb were selected, and thus, 24 fusions (Online Resource Section 6: Supplementary Table 4) were analyzed further. Among these 24 fusions, in-frame fusions were selected for candidate genetic hallmarks in R-GBM.

Selection of Genetic Hallmarks in R-GBM {#s0090}
---------------------------------------

We used WTS data to investigate functional genetic changes in R-GBM, and the public database was used as a reference. First, we compared the RPKM values of specific genetic changes found between tumor and normal brain tissue ([Figure 3](#f0015){ref-type="fig"}). We focused on affected genes with more than a 4-fold change in expression and integrated the results among WES, WTS, and array-CGH. Several genes had significant SNVs, CNAs, or fusions. Among genes with SNVs, *NDRG2*, *NKAIN2*, *CER1*, and *ISL1* were downregulated, whereas *PARP9* was upregulated in the tumor sample of the study patient compared to normal brain tissue. Among genes with CNAs, *NOTCH1*, *EGFR*, *CDK6*, *EZH2*, and *MET* were upregulated, whereas *CDKN2A* and *2B* were downregulated in the tumor sample of the study patient compared to normal brain tissue. These results are summarized in [Table 3](#t0015){ref-type="table"}.

The aforementioned analysis was assumed to have identified functional genetic changes in the selected genes. In addition, RPKM values of these selected genes in GBM and R-GBM were compared (genetic changes in GBM were obtained from the TCGA database). We listed genes with more than a 2-fold difference in genetic expression between conventional GBM and R-GBM. The following significant alterations between study samples (R-GBM) and conventional GBMs were found: 1) *CER1* and *ISL1* had SNVs that were significantly downregulated. 2) *CDKN2A* and *2B* were genes with CNAs and were significantly downregulated. 3) *NOTCH1*, *EGFR*, *CDK6*, *PIK3CA*, and *MET* were genes with CNAs and were significantly upregulated. 4) *PDK1, RASSF8, FKBP15, GALNT6, ITGA6, SLC6A6, TWIST2,and UPK3BL* were significantly up-regulated fusion genes correlated to R-GBM.

Search for GBMs With Similar Genetic Hallmarks in the TCGA Database {#s0095}
-------------------------------------------------------------------

In our case, genetic hallmarks excluding fusions are summarized below ([Table 3](#t0015){ref-type="table"}): 1) *BRAF* V600E; 2) *NDRG2* I92F and *ISL1* C234W mutation; 3) *CDKN2A/2B* homozygous loss; and 4) *EGFR*, *CDK6*, *EZH2*, *NOTCH1*, and *MET* copy number gain. Subsequently, we searched the cBioportal (TCGA provisional data) for GBM cases that also harbor the above mutations. For mutations, we used WES data (284 samples), and for gene copy number gain/loss, we used array-CGH data (497 samples).

Among 284 GBM cases with sequencing data, the *BRAF* V600E mutation was found in 1.7% of GBM cases. The *NDRG2* mutation was not found in GBM. However, when we searched for *NDRG2* genetic changes in the array-CGH database, *NDRG2* was amplified in two cases (2/497 = 0.4%) and homozygously deleted in three cases (3/497 = 0.6%). For *ISL1*, no mutation was found in GBM cases. However, the *ISL1* deletion was observed in two GBM cases (2/497 = 0.4%).

Based on array-CGH data from 497 GBM cases, homozygous deletions of *CDKN2A* and *CDKN2B* were found in 62% and 61% of the cases, respectively. Copy number gains of *EGFR*, *CDK6*, *EZH2*, *NOTCH1,* and *MET* were found in 49%, 7%, 4.4%, 0.6%, and 8.9% of the cases, respectively. Interestingly, *NOTCH1* copy number gain, and that of *EGFR*, *CDK6*, *EZH2*, and *MET*, were mutually exclusive. Two out of three *NOTCH1*-amplified cases accompanied the *CDKN2A/B* homozygous deletion. On the other hand, copy number gains in *EGFR*, *CDK6*, *EZH2*, and *MET* were not mutually exclusive, and co-amplification of these genes was frequently seen.

In three GBM cases with the *NDRG2* homozygous deletion, two had simultaneous homozygous *CDKN2A* and *CDKN2B* deletions. In addition, two of the three GBM cases with deleted *NDRG2* had a *NKX2-1* homozygous deletion. Regarding gene amplification, one of the three patients had *MET* and *EZH2* amplifications, and the other patient harbored *EGFR* amplification.

Among 198 GBM samples with both array-CGH and WES data, only one sample harbored the *BRAF* mutation, *MET*, *EGFR*, and *CDK6* amplifications, and *CDKN2A/B* homozygous deletion at the same time. However, no patient harbored the *BRAF* mutation and *NOTCH1* amplification at the same time. The *BRAF* mutation and *EZH2* amplification were also mutually exclusive. To summarize, although our case of R-GBM is not representative of all R-GBMs, coexistence of the genetic hallmarks found in our patient is a very rare event in GBM.

Discussion {#s0020}
==========

In this study, we addressed the genomic profile of R-GBM, a very rare disease entity. At the chromosomal level, we found copy number gains in chromosomes 3, 7, and 9, and the deletion of 9p21. When we correlate this karyotypic abnormality with genetic changes, we made the following observations.

On chromosome 3, *PIK3CA* was amplified, and its corresponding expression was elevated compared to normal brain. *PIK3CA* is frequently altered in GBM, and indeed, amplification of this gene is found in 13% of primary GBMs [@bb0135]. Hence, the *PIK3CA* copy number gain found in our sample was not surprising and implies that a common genetic denominator exists between GBM and R-GBM.

On chromosome 7, *EGFR*, *EZH2*, *CDK6*, and *MET* had copy number gain, and their expression was elevated compared to that in normal brain tissue. In fact, the gain of chromosome 7 along with *EGFR* and *MET* gene amplification is relatively common in adult brain tumors including GBM [@bb0140]. In addition, *EGFR* copy number gain and amplification were observed in a series of R-GBM cases [@bb0045; @bb0145]. On the other hand, amplification of *EZH2* and *CDK6* is not commonly observed; only 4% and 7% of GBM cases had amplification of these genes, respectively. Moreover, 1.2% of GBM cases had co-amplification of *EZH2* and *CDK6*, and 0.4% (2 out of 497) of GBM cases also had co-amplification of *MET*, *EZH2*, and *CDK6* according to the TCGA database. We reviewed the pathology slides of these two cases, which are detailed on the websites (cBioportal case_id=TCGA-06-0187 and cBioportal case ID=TCGA-19-1390). A pathology review of these two cases did not provide a definite diagnostic clue regarding R-GBM. Therefore, we could not draw a definite conclusion regarding whether amplification of one or more of *EZH2*, *CDK6*, or *MET* may be an irrelevant event or an oncogenic driver in the pathogenesis of R-GBM.

On chromosome 9, *NOTCH1* copy number gain and associated over-expression were observed. Although the role of the Notch pathway in brain tumors is an area of active investigation, Notch1 signaling is known to promote survival of GBM cells via EGFR-mediated signaling [@bb0150]. In addition, Notch signaling has oncogenic potential in a model of medulloblastoma [@bb0155]. Hence, we believe that the *NOTCH1* copy number gain found in our case may have substantially contributed to oncogenesis and tumor progression. However, only three among 497 cases had *NOTCH1* amplification in the TCGA database, which implies that this alteration in *NOTCH1* is not a common event in GBM. Regarding the genomic profile of these three cases, two harbored the *CDKN2A/2B* homozygous deletion as in our case, and one case harbored *TP53* and *IDH1* missense mutations. As mentioned in the Results section, *NOTCH1* amplification was mutually exclusive with *EGFR*, *MET*, *EZH2*, and *CDK6* amplification in the TCGA database. Hence, the simultaneous copy number gain in, and over-expression of, *NOTCH1*, *EGFR*, *MET*, *EZH2,* and *CDK6* in our sample is a very interesting phenomenon. What is most interesting regarding *NOTCH1* amplification is that one case with *NOTCH1* amplification in the TCGA database (cBioportal case id=TCGA-02-2483) had rhabdoid features upon pathology review. Therefore, we believe that further testing for *NOTCH1* copy number gain in other R-GBM samples is necessary to confirm whether *NOTCH1* is a key factor for rhabdoid morphogenesis.

For chromosome 9, the 9p21 deletion (rather than chromosome 9 copy number gain) was found using WES and SNP microarray. This alteration was not detected with conventional FISH, which confirms the high sensitivity of WES and SNP microarray compared to conventional FISH. Chromosome 9p21 contains *CDKN2A* and *CDKN2B*, which are well-known tumor suppressor genes that play an important role in GBM. *CDKN2A* and *CDKN2B* were homozygously deleted in this patient, and their expression was correspondingly low. Thus, *CDKN2A* and *CDKN2B* may play an important role in our patient.

As for non-synonymous SNVs excluding *BRAF* V600E, we designated the *ISL1* and *NDRG2* mutations as genetic hallmarks of R-GBM. We selected these genes for the following reasons. First, gene expression of *ISL1* and *NDRG2* was significantly reduced compared to expression in normal brain, which implies that these genetic changes are functional. Second, both *ISL1* and *NDRG2* are biologically relevant to brain tumor development. *ISL1* is required for neural development, and expression of this gene is associated with neuroendocrine carcinoma [@bb0160; @bb0165]. *NDRG2* is a well-known tumor suppressor in brain tumors [@bb0170]. In contrast to our sample, *ISL1* and *NDRG2* mutations were not found in the GBM TCGA database. Instead, homozygous deletion of *ISL1* (n = 2) and *NDRG2* (n = 3) was identified in a small subset (0.4% and 0.6%, respectively) of GBM cases in the TCGA database. As for the *NDRG2* deleted cases (n = 3) in the GBM (TCGA database), *KIT*, *PDGFRA*, and *CHIC2* amplifications were found in two cases (67%). Amplification of other oncogenes including *MET*, *EZH2*, *CDK4*, *and EGFR* was also identified. Interestingly, for tumor suppressor genes, *CDKN2A/2B* homozygous deletion (n = 2) and *NKX2-1* homozygous deletion (n = 2) were found in *NDRG2*-deleted GBMs. *NKX2-1* was also downregulated in our sample and was fused with *ARL6IP4* (Supplementary Table 4). Hence, these phenomena observed in the TCGA database coincide with the genetic changes found in our sample. More importantly, one case with the *NDRG2* deletion in the TCGA database (cBioportal case_id=TCGA-02-0281) showed possible GBM with rhabdoid features when we reviewed the histological images. Hence, we believe that loss of NDRG2 function may play an important role in R-GBM pathogenesis.

Finally, comparison of genetic changes in our case with those of ATRT is valuable because ATRT and R-GBM share common morphologic features. First, genes in the SWItch/Sucrose NonFermentable (SWI/SNF) complex, which is a genetic hallmark of ATRT [@bb0060; @bb0175; @bb0180], were not altered in R-GBM as had previously been shown. This finding suggests that although ATRT and R-GBM share common morphologic features, the SWI/SNF complex abnormality is not a key factor for rhabdoid morphogenesis. However, *EZH2* over-expression, which was recently shown to be important in ATRT [@bb0185], was observed in our sample. *EZH2* was both amplified and over-expressed in our sample. Therefore, *EZH2* copy number gain and over-expression may play an important role in rhabdoid tumor generation.

Here, we addressed genetic hallmarks found in our R-GBM case including *BRAF* V600E, *ISL1* C234W, *NDRG2* I92F, *CDKN2A/2B* deletion, *NOTCH1* copy number gain, and gain of chromosome 7 (including *CDK6*, *MET*, *EZH2*, and *EGFR* copy number gain). The patterns of mutation and gene expression in R-GBM are rather unique compared to conventional GBM, suggesting that R-GBM is a distinct disease entity. Among these genetic changes, *NOTCH1* copy number gain and *NDRG2* mutation, which are rare events in the TCGA GBM database, appear to be important genetic markers in R-GBM formation. Furthermore, *EZH2* copy number gain and over-expression may play an important role in rhabdoid tumorigenesis.

Appendix A. Supplementary data {#s0100}
==============================
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![Pathology of rhabdoid glioblastoma. (A) A representative H&E picture shows non-cohesive rhabdoid cells with eccentrically located pleomorphic nuclei and eosinophilic globular cytoplasm (H&E, original magnification × 200). (B) GFAP is robustly positive in some, but not all, tumor cells (GFAP immunostaining, original magnification × 200). (C) EMA is strongly positive in a cytoplasmic membrane pattern in almost all tumor cells (EMA immunohistochemistry, original magnification × 200). (D) Cyclin D1 (CCND1) staining is strongly positive in the nuclei of the tumor cells (cyclin D1 immunohistochemistry, original magnification × 200).](gr1){#f0005}

![Copy number status of R-GBM. (A) Gross copy number changes, (B) variant allele frequency in the tumor sample, and (C) variant allele frequency in the normal sample.](gr2){#f0010}

![Expression status of selected genetic changes found in the R-GBM sample in comparison with normal brain. (A) genetic changes with copy number alteration, (B) genetic changes with single nucleotide variation, and (C) genetic changes with gene fusion (y axis shows the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in normal brain (<http://www.brainspan.org>)).](gr3){#f0015}

###### 

List of 23 Candidate Non-Synonymous Somatic SNVs

  Chr     Position    dbSNP         Ref   Alt   Transcript       Gene        Effect     AA Change   Depth~N~   Depth~T~   VAF~N~   VAF~T~   RNA-Seq (confirmed)
  ------- ----------- ------------- ----- ----- ---------------- ----------- ---------- ----------- ---------- ---------- -------- -------- ---------------------
  Chr1    27876290    .             G     C     NM_001029882.2   *AHDC1*     MISSENSE   H779Q       81         66         0        0.409    O
  Chr1    104093621   .             C     G     NM_017619.3      *RNPC3*     MISSENSE   P474A       169        192        0        0.432    O
  Chr2    30748467    .             G     A     NM_182551.3      *LCLAT1*    NONSENSE   W42\*       266        259        0        0.409    X
  Chr2    209201623   .             G     A     NM_015040.3      *PIKFYVE*   MISSENSE   G1528R      182        174        0        0.379    O
  Chr3    52413954    .             G     A     NM_015512.4      *DNAH1*     MISSENSE   E2471K      15         34         0        0.294    O
  Chr3    122247474   .             T     C     NM_031458.2      *PARP9*     MISSENSE   T768A       234        300        0        0.563    O
  Chr5    50685703    .             C     G     NM_002202.2      *ISL1*      MISSENSE   C234W       78         77         0        0.455    X
  Chr6    124604235   .             G     A     NM_001040214.1   *NKAIN2*    MISSENSE   V47I        278        264        0        0.371    X
  Chr7    42962956    .             C     T     NM_002787.4      *PSMA2*     MISSENSE   G142R       169        176        0        0.477    O
  Chr7    99170311    .             A     T     NM_001083956.1   *ZNF655*    MISSENSE   M229L       183        204        0        0.309    O
  Chr7    140453136   rs113488022   A     T     NM_004333.4      *BRAF*      MISSENSE   V600E       208        294        0        0.551    O
  Chr9    14720261    .             G     A     NM_005454.2      *CER1*      MISSENSE   P211S       163        183        0.006    0.874    X
  Chr10   100189389   .             C     G     NM_000195.3      *HPS1*      MISSENSE   S293T       64         63         0        0.397    O
  Chr11   799344      .             G     A     NM_145886.3      *PIDD*      MISSENSE   S899F       53         67         0        0.373    O
  Chr11   124766873   .             G     A     NM_019055.5      *ROBO4*     MISSENSE   R119W       25         23         0        0.478    X
  Chr12   49237760    .             C     G     NM_004818.2      *DDX23*     MISSENSE   D95H        345        269        0        0.353    O
  Chr14   21490291    .             T     A     NM_201537.1      *NDRG2*     MISSENSE   I92F        148        148        0        0.338    X
  Chr18   54424349    .             G     A     NM_015285.2      *WDR7*      MISSENSE   G842D       317        318        0.003    0.374    O
  Chr19   6772990     .             C     T     NM_005428.3      *VAV1*      MISSENSE   R58C        154        139        0        0.36     X
  Chr19   13211542    rs149285767   C     T     NM_005583.4      *LYL1*      MISSENSE   G119E       283        238        0        0.176    O
  Chr22   40417337    .             C     A     NM_138435.2      *FAM83F*    MISSENSE   L275I       283        257        0        0.416    X
  ChrX    49840621    .             T     A     NM_001127899.2   *CLCN5*     MISSENSE   I196N       165        141        0        0.142    X
  ChrX    111698369   .             A     G     NM_001004308.2   *ZCCHC16*   MISSENSE   K138R       298        290        0        0.41     X

Chr, Chromosome; Ref, Reference; Alt, Alternative; AA, amino acid; VAF, Variant allele frequency.

###### 

Genes with Copy Number Alterations that Are Well Known to be Associated with Cancer Development and/or Progression

  Chr    Start       End         Gene       Genetic alteration   aCGH   WES   SNP array   Classification   Expression Ratio1[⁎](#tf0005){ref-type="table-fn"}   Expression Ratio2[\#](#tf0015){ref-type="table-fn"}
  ------ ----------- ----------- ---------- -------------------- ------ ----- ----------- ---------------- ---------------------------------------------------- -----------------------------------------------------
  Chr3   9022276     9291369     *VHL*      Gain                 Yes    Yes   Yes         TSG              − 0.28                                               3.07
  Chr3   41240942    41281939    *CTNNB1*   Gain                 Yes    Yes   Yes         Oncogene         − 0.04                                               5.83
  Chr3   178916609   178922393   *PIK3CA*   Gain                 Yes    Yes   Yes         Oncogene         1.93                                                 2.92
  Chr7   55086951    55214485    *EGFR*     Gain                 Yes    Yes   Yes         Oncogene         3.02                                                 1.54
  Chr7   92234235    92465941    *CDK6*     Gain                 Yes    Yes   Yes         Oncogene         3.05                                                 1.86
  Chr7   116312459   116438440   *MET*      Gain                 Yes    Yes   Yes         Oncogene         4.32                                                 3.83
  Chr7   148504464   148581441   *EZH2*     Gain                 Yes    Yes   Yes         Oncogene         5.29                                                 0.12
  Chr7   151832010   152133090   *MLL3*     Gain                 Yes    Yes   Yes         Oncogene         0.84                                                 1.94
  Chr9   21967751    21994490    *CDKN2A*   Loss                 Yes    Yes   Yes         TSG              − 2.38                                               − 1.03
  Chr9   22005935    22009013    *CDKN2B*   Loss                 Yes    Yes   Yes         TSG              − 3.02                                               − 8.89
  Chr9   139388896   139440238   *NOTCH1*   Gain                 Yes    Yes   Yes         Oncogene         2.37                                                 2.77

Chr, chromosome; aCGH, array comparative genomic hybridization; WES, whole exome sequencing; Del, deletion; TSG, tumor suppressor gene.

Expression ratio 1 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in normal brain (<http://www.brainspan.org>).

Expression ratio 2 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in glioblastoma multiforme (<https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp>).

###### 

Genetic Hallmarks of Rhabdoid Glioblastoma.

  Chr     Position    Change    Gene       Amino Acid Change   Ratio1[⁎](#tf0010){ref-type="table-fn"}   Ratio2[\#](#tf0020){ref-type="table-fn"}   Frequency in GBM   Other Changes Involving This Gene in GBM
  ------- ----------- --------- ---------- ------------------- ----------------------------------------- ------------------------------------------ ------------------ ------------------------------------------
  Chr5    50678958    SNV       *ISL1*     C234W               − 2.62                                    − 6.78                                     0%                 Deletion (0.4%)
  Chr7    140453136   SNV       *BRAF*     V600E               0.50                                      1.85                                       1.7%               Amplification (4.4%), deletion (0.2%)
  Chr14   21490291    SNV       *NDRG2*    I92F                − 7.16                                    4.80                                       0%                 Amplification (0.4%), deletion (0.6%)
  Chr3    178916609   CN gain   *CDK6*     NA                  3.05                                      1.86                                       7%                 Mutation (26%)
  Chr7    55086725    CN gain   *EGFR*     NA                  3.02                                      1.54                                       49%                None
  Chr7    116335706   CN gain   *MET*      NA                  4.32                                      3.83                                       8.9%               Mutation (0.7%)
  Chr7    148504464   CN gain   *EZH2*     NA                  5.29                                      0.12                                       4.4%               Mutation (1.1%)
  Chr9    139388896   CN gain   *NOTCH1*   NA                  2.37                                      2.77                                       0.6%               None
  Chr9    21968144    CN loss   *CDKN2A*   NA                  − 2.38                                    − 1.03                                     62%                Mutation (0.7%)
  Chr9    22005935    CN loss   *CDKN2B*   NA                  − 3.02                                    − 8.89                                     61%                Mutation (0.4%)

Chr, chromosome; CN, copy number; GBM, glioblastoma multiforme; SNV, single nucleotide variant; NA, not applicable.

Ratio 1 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in normal brain (<http://www.brainspan.org>).

Ratio 2 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in glioblastoma multiforme (<https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp>).

[^1]: These authors contributed equally to this study.
